The science, in full.

Background: Cannabidiol (CBD) is a non-psychoactive phytocannabinoid with growing interest for health and wellness applications. However, oral CBD bioavailability is limited by poor aqueous solubility and extensive first-pass metabolism. This study evaluated two novel CBD formulations developed using Micro Matrix Technology against a standard CBD isolate reference.

Methods: A randomized, single-dose, three-way crossover study was conducted in 9 healthy adult volunteers under fed (low-fat) conditions. Subjects received 40 mg CBD as: (1) CBDNext Supra Capsule (solid matrix formulation with polysorbate 80, maltodextrin, stearic acid, silica derivative), (2) CBDNext Supra Liquid (liquid formulation), or (3) Reference capsule (CBD isolate with microcrystalline cellulose). Blood samples were collected over 72 hours. Plasma CBD and 7-hydroxy-CBD concentrations were measured by validated LC-MS/MS.

Results — CBD Pharmacokinetics: • Supra Capsule: Cmax 14.1 ng/mL, AUC₀₋₇₂ 38.0 h·ng/mL, median Tmax 2.0 h, CV% ~27% • Supra Liquid: Cmax 6.20 ng/mL, AUC₀₋₇₂ 20.2 h·ng/mL, median Tmax 1.0 h, CV% ~44% • Reference: Cmax 2.44 ng/mL, AUC₀₋₇₂ 11.7 h·ng/mL, median Tmax 6.0 h, CV% ~134%

Geometric Mean Ratios (90% CI): • Capsule vs Reference — Cmax: 566% (356–900%), AUC: 328% (226–478%) • Liquid vs Reference — Cmax: 248% (156–394%), AUC: 166% (114–241%) • Capsule vs Liquid — Cmax: 229% (140–374%), AUC: 198% (136–288%)

7-Hydroxy-CBD Metabolite: • Capsule: Cmax 1.8 ng/mL, AUC 8.0 h·ng/mL • Liquid: Cmax 1.0 ng/mL, AUC 4.5 h·ng/mL • Reference: Cmax 0.4 ng/mL, AUC 1.8 h·ng/mL

Safety: No serious adverse events were reported. The only treatment-related adverse event was mild-to-moderate transient headache in 4 subjects. No clinically significant changes in liver function tests. Plasma cortisol remained within normal ranges throughout all study periods.

Conclusions: The CBDNext Supra Capsule formulation demonstrated substantially enhanced CBD bioavailability compared to standard CBD isolate, with approximately 5.7-fold higher peak plasma concentration and 3.3-fold greater total exposure. Both novel formulations showed markedly reduced inter-subject variability, suggesting more predictable and consistent CBD delivery. The solid matrix formulation (Supra Capsule) outperformed the liquid formulation across all pharmacokinetic parameters.

Authors: Pisak MN, Bereket E, Erenmemisoglu A Published: Journal of Cannabis Research, Volume 7, Article 54 (2025) Publisher: Springer Nature / BioMed Central

Study Design: Open-label clinical trial conducted in 32 children with recurrent respiratory tract infections. Subjects received 10 mg micronized beta-glucan (≥70% purity, minimum 80% of particles ≤10 µm) daily during flu season.

Population: Children with documented history of recurrent respiratory tract infections, tracked during high-incidence period.

Key Specifications of Test Material: • Source: Saccharomyces cerevisiae (baker's yeast) cell wall • Beta-glucan assay: minimum 70% • Particle size: minimum 80% ≤10 µm (micronized) • Total lipid: <1%, Total ash: <6%, Total protein: <3% • Microbiological count: <1000 CFU/g

Results: • 14 of 32 children (44%) had no respiratory tract infections after supplementation • 26 of 32 children (81%) showed at least 75% reduction in RTI cases per month • Overall 81% reduction in RTI occurrence during the testing period vs pre-supplementation baseline • No adverse effects reported during the study period

Mechanism: Micronized beta-(1,3)-(1,6)-glucan from baker's yeast acts as a non-specific immune activator. After oral ingestion, beta-glucan particles reach Peyer's patches and gut-associated lymphoid tissue (GALT), where they stimulate innate immune responses including activation of NK cells, T cells, B cells, macrophages, monocytes, and neutrophils via increased cytokine production.

Note: This study was conducted on the micronized beta-glucan component, which is one of three active ingredients in the ImmuCurc formula. Results are specific to this component under the reported study conditions.

Study 1 — Advanced Breast Cancer (Monocyte Activation): Patients with advanced breast cancer received micronized beta-glucan as adjuvant to standard chemotherapy.

Results at Day 15: • Mean monocyte count: increased from 326 ± 124/mm³ to 496 ± 194/mm³ (p = 0.015) • Monocyte percentage: increased from 7.4% to 12% (p = 0.003) • CD95 expression on CD14+ monocytes: 48.17% to 69.23% (p = 0.002) • CD45RA expression on CD14+ monocytes: 49.9% to 61.52% (p = 0.001)

Study 2 — Head & Neck Cancer (Oral Mucositis): Three chemotherapy cycles; beta-glucan group received 10 mg/day (≤60 kg) or 20 mg/day (>60 kg) in addition to chemotherapy.

Results: • Less leukocyte decline during chemotherapy cycles • Significantly lower oral mucositis severity scores • No side effects reported over three months of supplementation

Study 3 — Allergic Rhinitis (Th1/Th2 Rebalancing): Subjects with allergic rhinitis received micronized beta-glucan with nasal provocation testing and cytokine analysis.

Results: • IL-12 increased significantly (p = 0.008) • IL-4 decreased (p = 0.027) • IL-5 decreased (p = 0.04) • Eosinophil percentage significantly decreased vs no change in placebo group • Demonstrates shift from Th2-dominant (allergic) toward balanced Th1/Th2 immune profile

Note: These studies were conducted on the micronized beta-glucan component. Results are specific to this ingredient under the reported study conditions.

Background: Curcumin has demonstrated broad biological activity but suffers from extremely poor aqueous solubility (<0.01 mg/mL) and low oral bioavailability. NovoCurmin™ is a reformulated curcumin complex developed using Micro Matrix Technology, protected by 2 international patent applications.

Solubility Study: Water solubility comparison (mg/mL): • NovoCurmin™: ~89 mg/mL • Competitor 1 (phytosomal): ~21 mg/mL • Competitor 2: ~25 mg/mL • Competitor 3: ~22 mg/mL • Competitor 4: ~9 mg/mL • Standard curcumin extract: ~1–2 mg/mL

Pharmacokinetic Comparison (single-dose, equivalent curcuminoid loading): • NovoCurmin Powder: Cmax 31,322 ng/mL, Tmax 1 h, AUC₀₋₈ₕ 84,440 h·ng/mL • Curcumin API (standard): Cmax 2,199 ng/mL, Tmax 0.5 h, AUC₀₋₈ₕ 9,606 h·ng/mL • Phytosome Competitor: Cmax 5,794 ng/mL, Tmax 8 h, AUC₀₋₈ₕ 28,711 h·ng/mL • Gamma-cyclodextrin Competitor: Cmax 13,053 ng/mL, Tmax 4 h, AUC₀₋₈ₕ 74,058 h·ng/mL

Fold Improvements vs Standard Curcumin: • Cmax: ~14× higher • AUC: ~8.8× greater • vs Phytosome competitor: 5.4× higher Cmax, 2.9× greater AUC • vs Gamma-cyclodextrin: 2.4× higher Cmax

Key Advantages: • Suitable for beverages, food, supplements, and pharmaceutical applications • Higher curcumin loading per mg vs competitors • Lower emulsifier use • DMF-grade extract • Powder or liquid ready-to-fill formats • cGMP manufacturing • Uses only GRAS excipients accepted by major regulatory authorities worldwide

Note: This is preclinical characterisation data. Human clinical studies on NovoCurmin as a standalone product are in development.

Background: Cannabinoids are hydrophobic compounds with extremely poor water solubility. Improving solubility alone does not guarantee bloodstream absorption. CannabiNext was developed to address both solubility and systemic bioavailability using Micro Matrix Technology.

Water Solubility Comparison (mg/mL): • CannabiNext: ~57 mg/mL • Leading competitor: ~10 mg/mL • Cyclodextrin complex: ~2 mg/mL • Standard CBD: ~2 mg/mL

Maximum Cannabinoid Concentration (mg/L): • CannabiNext CBD: 59,000 mg/L • Leading competitor: 9,000–11,000 mg/L • Regular CBD: 15 mg/L

CannabiNext Neutron PK Data (first-generation): • CannabiNext CBD: Cmax 486 ng/mL, Tmax 0.50 h, AUC 1,615 h·ng/mL • Standard CBD: Cmax 15 ng/mL, Tmax 0.50 h, AUC 58 h·ng/mL • Result: 32× higher blood concentration vs regular CBD

CannabiNext Supra PK Data (second-generation): • Supra Powder: Cmax 1,560 ng/mL, Tmax 0.083 h, AUC₀₋₈ₕ 4,662 h·ng/mL • Supra Liquid: Cmax 1,336 ng/mL, Tmax 0.083 h, AUC₀₋₈ₕ 2,227 h·ng/mL • Standard CBD: Cmax 17.48 ng/mL, Tmax 0.5 h, AUC₀₋₈ₕ 61 h·ng/mL • Result: 88× higher Cmax, ~3× higher than vaping/smoking, 44× bioavailability ratio

Platform Advantages: • Suitable for beverages, edibles, and other cannabinoid products • Neutral taste profile • Consistent batch-to-batch control • Uses only GRAS excipients • Accepted by major global regulatory authorities • Powder and liquid delivery formats available • Easy manufacturing integration

Note: CannabiNext is a platform technology. The CBDNext Supra Capsule human PK study (published in Journal of Cannabis Research, 2025) provides finished-product human evidence for one specific formulation built on this platform.